Literature DB >> 12579331

Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis.

Kosuke Tobita1, Hiroshi Kijima, Shoichi Dowaki, Hiroyuki Kashiwagi, Yasuo Ohtani, Yasuhisa Oida, Hitoshi Yamazaki, Masato Nakamura, Yoshito Ueyama, Makiko Tanaka, Sadaki Inokuchi, Hiroyasu Makuuchi.   

Abstract

Pancreatic cancer is a malignant tumor with an extremely poor prognosis. The mechanisms of the aggressive growth and metastasis are not yet extensively understood. Over-expression of epidermal growth factor receptor (EGFR) was suggested to be associated with malignant transformation of pancreatic cancer. We examined EGFR expression in 77 cases of invasive ductal adenocarcinoma of the pancreas, and analyzed the relation between the EGFR expression pattern and clinicopathological factors. EGFR immunoreactivity was detected in 41.6% (32/77) of human pancreatic cancers; i.e. diffuse expression in 32.5% (25/77) and focal expression in 9.1% (7/77). The EGFR expression was associated with gender (p<0.05), histological differentiation (p<0.05) and metastatic status of TNM classification (p<0.01). The observations suggested that EGFR expression plays important roles in metastasis, especially liver metastasis and recurrence of human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12579331

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  81 in total

Review 1.  Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Authors:  Jie-Er Ying; Li-Ming Zhu; Bi-Xia Liu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma.

Authors:  Kwang Yeol Paik; Seong Ho Choi; Jin Seok Heo; Dong Wook Choi
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

3.  Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Hyunki Kim; Karri D Folks; Lingling Guo; Jeffery C Sellers; Naomi S Fineberg; Cecil R Stockard; William E Grizzle; Donald J Buchsbaum; Desiree E Morgan; James F George; Kurt R Zinn
Journal:  Mol Imaging       Date:  2011-06       Impact factor: 4.488

4.  Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.

Authors:  Guojun Chen; Yuyuan Wang; Ruosen Xie; Shaoqin Gong
Journal:  J Control Release       Date:  2017-02-01       Impact factor: 9.776

5.  Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.

Authors:  Ying-Ying Lu; Da-Dao Jing; Ming Xu; Kai Wu; Xing-Peng Wang
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 6.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Authors:  Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos
Journal:  Ann Transl Med       Date:  2016-05

7.  Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.

Authors:  Zhimin Tong; Subhankar Chakraborty; Bokyung Sung; Pooja Koolwal; Sukhwinder Kaur; Bharat B Aggarwal; Sendurai A Mani; Robert S Bresalier; Surinder K Batra; Sushovan Guha
Journal:  Cancer       Date:  2010-12-29       Impact factor: 6.860

8.  Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Aamir Ahmad; Bassel F El-Rayes; Philip A Philip; Fazlul H Sarkar
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

9.  Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.

Authors:  Guy A Weiss; Michael R Rossi; Nikhil I Khushalani; Ken Lo; John F Gibbs; Anubha Bharthuar; John K Cowell; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2013-03

10.  Erlotinib in the treatment of advanced pancreatic cancer.

Authors:  Robin K Kelley; Andrew H Ko
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.